Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry

Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56(bright) subpopulation of NK cells that is...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Ranganath, Thanmayi, Simpson, Laura J., Ferreira, Anne-Maud, Seiler, Christof, Vendrame, Elena, Zhao, Nancy, Fontenot, Jason D., Holmes, Susan, Blish, Catherine A.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7194113/
https://ncbi.nlm.nih.gov/pubmed/32391016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00714
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars